Insulet Corporation (PODD)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
$2.12 (-0.79%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Insulet Corporation (PODD)
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 425,000 insulin-dependent diabetics are using it worldwide.

Key Insights

Critical company metrics and information
  • Share Price

    $265.46
  • Market Cap

    $18.62 Billion
  • Total Outstanding Shares

    70.15 Million Shares
  • Total Employees

    3,000
  • Dividend

    No dividend
  • IPO Date

    May 15, 2007
  • SIC Description

    Surgical & Medical Instruments & Apparatus
  • Homepage

    https://www.insulet.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Investing Activities$-109.80 Million
Net Cash Flow, Continuing$213.00 Million
Net Cash Flow From Operating Activities, Continuing$327.80 Million
Net Cash Flow From Investing Activities, Continuing$-109.80 Million
Net Cash Flow From Operating Activities$327.80 Million
Net Cash Flow From Financing Activities, Continuing$-5.00 Million
Net Cash Flow From Financing Activities$-5.00 Million
Net Cash Flow$217.20 Million
Exchange Gains/Losses$4.20 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Income/Loss Attributable To Parent$420.90 Million
Operating Expenses$1.07 Billion
Revenues$1.98 Billion
Selling, General, and Administrative Expenses$869.00 Million
Gross Profit$1.38 Billion
Benefits Costs and Expenses$1.69 Billion
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Operating Income/Loss$306.00 Million
Research and Development$201.00 Million
Income Tax Expense/Benefit$-124.20 Million
Net Income/Loss Available To Common Stockholders, Basic$420.90 Million
Income/Loss From Continuing Operations After Tax$420.90 Million
Costs And Expenses$1.69 Billion
Diluted Average Shares$77.35 Million
Basic Average Shares$70.08 Million
Net Income/Loss$420.90 Million
Basic Earnings Per Share$6.01
Income/Loss From Continuing Operations Before Tax$296.70 Million
Preferred Stock Dividends And Other Adjustments$0.00
Diluted Earnings Per Share$5.87
Cost Of Revenue$607.90 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Assets$3.03 Billion
Inventory$444.90 Million
Other Current Assets$1.42 Billion
Noncurrent Assets$1.16 Billion
Liabilities And Equity$3.03 Billion
Noncurrent Liabilities$1.40 Billion
Equity Attributable To Noncontrolling Interest$0.00
Current Liabilities$506.20 Million
Other Current Liabilities$465.90 Million
Equity Attributable To Parent$1.12 Billion
Equity$1.12 Billion
Accounts Payable$40.30 Million
Liabilities$1.91 Billion
Current Assets$1.86 Billion

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.